Clinipace Worldwide Joins American Society of Nephrologys Kidney Health Initiative
Company News: Page (1) of 1 - 05/19/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Clinipace Worldwide Joins American Society of Nephrologys Kidney Health Initiative (May 19, 2017)

Move is Part of Companys Expanded Commitment to Nephrology

MORRISVILLE, N.C.--(BUSINESS WIRE)--#clinicalresearch--Clinipace Worldwide, a global digital contract research organization (dCRO), announced today that it has become a member of the American Society of Nephrologys Kidney Health Initiative (KHI).


The KHI mission is to advance scientific understanding of the kidney health and patient safety implications of new and existing medical products, and to foster development of therapies for diseases that affect the kidney. The initiative plans to achieve this by creating a collaborative environment in which the U.S. Food and Drug Administration and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.

?The decision to join the ASN Kidney Health Initiative is an important element in our expanded commitment to the nephrology field, said Clinipace President and CEO Jeff Williams. ?We fully support the KHI goal of improving patient safety and promoting development of new therapies for all patients with kidney disease, a major public health issue that affects up to 26 million Americans.


Clinipace representatives will attend the Fifth Annual KHI Stakeholders Meeting in Washington, DC, on May 24-25, 2017. This meeting will bring together the diverse membership of the KHI from the kidney community to connect members across different fields, share ideas, collect feedback, and collaborate on new and proposed projects.

Also in this therapeutic area, in April 2017, Clinipace appointed eminent nephrologist Eric B. Grossman, MD, as Vice President and Medical Director. With over 30 years of industry and clinical experience, Dr. Grossman brings almost two decades of experience designing and conducting clinical studies in therapeutic areas including nephrology, cardiovascular, diabetes, urology, womens health and oncology. Dr. Grossman previously held positions with Bexon Clinical Consulting, Reata Pharmaceuticals, Keryx Biopharmaceuticals, the New York Organ Donor Network and Pfizer. Dr. Grossman received an MD from the University of Chicago Pritzker School of Medicine. He completed his residency at the Tufts-New England Medical Center and his nephrology fellowship at Harvard Medical Schools Brigham and Womens Hospital in Boston.

About Clinipace Worldwide

Clinipace Worldwide, a digital contract research organization (dCRO), pioneered an innovative, technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms.

Powered by Clinipaces proprietary TEMPO eClinical platform and a team of experts with extensive knowledge in therapeutic areas such as oncology, cardiovascular, and metabolic diseases, gastroenterology, infectious diseases, nephrology, immunology and vaccines, the company assists life science firms in successfully executing regulatory strategies, clinical development and post-approval research programs. To learn more, visit www.Clinipace.com.


Contacts

Clinipace Worldwide
Sandra Parrish Woodlief, 919-797-9480
swoodlief@clinipace.com


Page: 1


Related Keywords:



Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved